#DYK

Did you

know?

CERVICAL CANCER (CC) GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

Asia had the highest incidence cases and accounted for nearly 60% of the global incidence cases of CC

Africa had the **second highest incidence**, with over 125,700 cases

Latin America and the Caribbean had more than 63,100 cases, followed by Europe and North America



The CC treatment market offers diverse products by companies including **Akeso Inc.**, **Amgen Inc.**, **Baxter International Inc.**, and **Merck & Co. Inc.**



8th MOST DIAGNOSED

CANCER

2022: NEARLY 6662k NEW CASES

Multiple ongoing **Phase III trials** demonstrate continued efforts to **enhance CC treatment through cellular vaccines**, **antibody**, **and small molecules**

LEADING CAUSE OF CANCER MORTALITY



CERVICAL CANCER TRIAL CONTRIBUTIONS

Countries like **Mainland China, United States, Spain, Australia,** and **South Korea** emerged as **top locations** for conducting trials

Asia-Pacific showed faster recruitment durations

48% ASIA-PACIFIC

46%

NORTH AMERICA & EUROPE

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com